Trial Profile
A Prospective Randomized, Open, Multi-Center Trial Comparing TNF-Blockade + MTX to MTX+SSZ+HCQ in Patients With Early RA With an Inadequate Response to MTX.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Nov 2020
Price :
$35
*
At a glance
- Drugs Infliximab (Primary) ; Hydroxychloroquine; Methotrexate; Sulfasalazine
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms SWEFOT
- 12 Nov 2020 Results comparing mortality risk over fourteen years of follow-up published in the Rheumatology
- 01 Feb 2019 Results (n=298) of patients from the Swedish Pharmacotherapy (SWEFOT) clinical trial, assessing baseline serum levels of 12 protein for association with disease activity based on the 28-joint count Disease Activity Score (DAS28) after 3 months of MTX monotherapy, published in The Journal of Rheumatology.
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism